COSTS OF R&D
KEI has put together an overview of different estimates of drug development costs. Those estimates have been published by academics, organisations and institutes. KEI compared their diverse calculations.
The Portfolio-To-Impact (P2I) Model allows users to model scenarios and estimate the costs of developing health technologies for neglected diseases. The Supplementary Files contain data on average R&D costs per phase by technology type, length of phase, and probability of success; data on the current neglected disease product pipeline is also included.